Diltiazem Hydrochloride Capsules Recalled Due to Nitrosamine Impurity
Glenmark Pharmaceuticals is recalling Diltiazem Hydrochloride capsules because they contain a chemical impurity above safe limits. About 7,296 bottles were distributed nationwide.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA Class II recall involving a manufacturing defect with N-nitroso-Desmethyl-Diltiazem impurity above FDA's recommended interim limit. No illnesses or injuries are reported. This constitutes a risk-of-harm pharmaceutical product without yet-reported injury.
Plain-English summary
Glenmark Pharmaceuticals Inc., USA is recalling Diltiazem Hydrochloride Extended-Release Capsules, USP 120mg, distributed nationwide in the United States. Approximately 7,296 bottles are affected. The product was manufactured by Glenmark Pharmaceuticals Limited in Pithampur, India, and distributed by Northstar Rx LLC in Memphis, Tennessee.
The recall is due to a manufacturing quality defect: the presence of N-nitroso-Desmethyl-Diltiazem, a chemical impurity, at levels exceeding FDA's recommended interim limit. This represents a deviation from current Good Manufacturing Practice (cGMP) standards.
The affected lots are: #17222547 (expiration date 11/30/2024) and #17230598 (expiration date 02/28/2025). Patients currently taking this medication should contact their healthcare provider or pharmacist for guidance. Do not discontinue use without medical advice. Consumers with unused product should return it to their pharmacy.
The recalled product
- Product
- DILTIAZEM HYDROCHLORIDE (DILTIAZEM HYDROCHLORIDE)
- Brand
- DILTIAZEM HYDROCHLORIDE
- Manufacturer
- Glenmark Pharmaceuticals Inc., USA
- Category
- Drug
- Hazard
- nitrosamine-impurity
- manufacturing-defect
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (5)
- Lot #:17222547
- Exp. Date
- 11/30/2024
- 17230598
- Exp. Date 02/28/2025
UPCs (3)
- 0316714555010
- 0316714553016
- 0316714554013
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · DILTIAZEM HYDROCHLORIDE
- HighGlenmark Diltiazem Extended-Release Capsules recalled for manufacturing deviations
FDA (Drugs) · 2025-04-16
- HighDiltiazem extended-release capsules recalled for manufacturing impurity
FDA (Drugs) · 2024-12-11
- HighDiltiazem Hydrochloride Extended-Release Capsules Recalled for Manufacturing Impurity
FDA (Drugs) · 2024-12-11
- HighDiltiazem Hydrochloride Capsules Recalled Due to Manufacturing Impurity
FDA (Drugs) · 2024-12-11
- HighPrescription Drug Diltiazem Hydrochloride Recalled for Manufacturing Impurity
FDA (Drugs) · 2024-12-11
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27